Investors / Spain / Criteria Bio Ventures
Criteria Bio Ventures
Corporate VC · Barcelona, Spain · Europe
Criteria Bio Ventures is the life sciences venture capital vehicle of Criteria Capital Risc, the venture capital arm of CriteriaCaixa, which manages the wealth of the "la Caixa" Foundation. It invests in private biotechnology and health companies, providing capital and strategic support, and also supports the CaixaImpulse technology transfer programme.
Invests inHealthcare & Biotech
In its own wordsbiotechlife scienceshealthcaretherapeuticstechnology transfer
Your fit with Criteria Bio Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsCriteria Bio Ventures lists 14 checked portfolio companies on its own site and is named in 3 funding rounds, 1 of them as lead. Its most frequent entry is Seed, 33% of the companies with a known first round. Its largest themes are Healthcare & Biotech (87%), Food & Agriculture (7%) and Industrial & Manufacturing (7%). 55% of its companies are based in Spain. It invests most often alongside Ysios Capital, Asabys Partners and British Business Bank.
Counts come from funding rounds that name Criteria Bio Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Criteria Bio Ventures' whole history. Rounds on record name 3 companies; its own site lists 14. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 33% |
| Series A | 33% |
| Series B | 33% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 1 |
| '26 | 1 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 36th | 14 companies |
| Recent activity | 59th | 1 rounds in 12 months |
| Early stage | 64th | 33% of entries at pre-seed or seed |
| Evidence | 93th | 21% of companies confirmed by a round |
| Sector focus | 95th | 87% in its largest sector |
| Reach | 78th | 5 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Ysios Capital | 3 |
| Asabys Partners | 2 |
| British Business Bank | 2 |
| Novartis Venture Fund | 2 |
| Sound Bioventures | 2 |
| 4BIO Capital | 1 |
| Abingworth | 1 |
| BAMCAP Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers1393%
- No longer answers00%
- Points to another company17%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 87% | 15% |
| Food & Agriculture | 7% | 3% |
| Industrial & Manufacturing | 7% | 7% |
Co-investor network
who it backs companies with, and who they back togetherCompare Criteria Bio Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Criteria Bio Ventures| Date | Company | Stage |
|---|---|---|
| 5 May 2026 | Series A | |
| 27 Oct 2025 | Seed Led | |
| 8 Sept 2025 | Series B |
Round details for Criteria Bio Ventures
Amounts, full round histories and every co-investor in Criteria Bio Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
14 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Aboleris Pharma is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and organ transplantation rejection. | Healthcare & Biotech | Portfolio page | ||
| Adaptam Therapeutics is developing antibody-based therapies directed to novel targets to bring better therapies to oncology patients. | Healthcare & Biotech | Oct 2025Seed | Page + round | |
| AptaTargets is a clinical-stage biotechnology company that develops therapeutic applications based on aptamer technology | Healthcare & Biotech | Portfolio page | ||
Healthcare & BiotechFood & Agriculture | Portfolio page | |||
| Cytospire Therapeutics develops next generation immune cell engagers, including multispecific antibodies and gamma delta T cell engagers, for cancer therapies. | Healthcare & Biotech | May 2026Series A | Page + round | |
| Devicare develops products based on scientific evidence for the care and prevention of urinary health. | Healthcare & Biotech | Portfolio page | ||
| Inbiomotion develops a test to help select breast cancer patients for adjuvant treatment with bisphosphonates | Healthcare & Biotech | Portfolio page | ||
| Minoryx Therapeutics discovers and develops novel treatments for severe orphan diseases of the central nervous system | Healthcare & Biotech | Portfolio page | ||
| Northern Biologics develops therapeutic antibodies for cancer treatment | Healthcare & Biotech | Portfolio page | ||
| NRG Therapeutics is developing innovative oral medicines for amyotrophic lateral sclerosis and Parkinson's | Healthcare & Biotech | Sept 2025Series B | Page + round | |
| Nuubo offers a non-invasive and wireless monitoring technology based on textiles for medium and long-term monitoring | Healthcare & Biotech | Portfolio page | ||
| SpliceBio is a genetic medicines company that develops gene therapies using its proprietary Protein Splicing platform. | Healthcare & Biotech | Portfolio page | ||
| Tolerance Bio increases health span by preserving, restoring, and modulating the function of the thymus, the master regulator of immune tolerance | Healthcare & Biotech | Portfolio page | ||
| Wooptix is a semiconductor wafer metrology innovator that provides high-resolution and precise metrology equipment | Industrial & Manufacturing | Portfolio page |
About this data
site last read 11 Nov 2026- Site
- criteriabioventures.com
- Last read
- 11 Nov 2026
- Watching since
- 8 Nov 2026
- Rounds since
- 8 Sept 2025
- Companies checked
- 14
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Criteria Bio Ventures' profile as data
Pull Criteria Bio Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/criteriabioventures.com
# also
GET /v1/firms/criteriabioventures.com/portfolio
GET /v1/firms/criteriabioventures.com/coinvestors
GET /v1/firms/criteriabioventures.com/news